A Prospective, Randomized, Crossover-Design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis.
Phase of Trial: Phase I/II
Latest Information Update: 28 Aug 2015
At a glance
- Drugs Daptomycin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Cubist Pharmaceuticals
- 16 Sep 2011 Actual patient no is 16 and trial phase changed from I to II as reported by ClinicalTrials.gov.
- 05 Aug 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 05 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.